Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

AX. Zhu, JO. Park, BY. Ryoo, CJ. Yen, R. Poon, D. Pastorelli, JF. Blanc, HC. Chung, AD. Baron, TE. Pfiffer, T. Okusaka, K. Kubackova, J. Trojan, J. Sastre, I. Chau, SC. Chang, PB. Abada, L. Yang, JD. Schwartz, M. Kudo, . ,

. 2015 ; 16 (7) : 859-70. [pub] 20150618

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15031316
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 26095784
DOI 10.1016/s1470-2045(15)00050-9
Knihovny.cz E-zdroje

BACKGROUND: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. METHODS: In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy, had Child-Pugh A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, had previously received sorafenib (stopped because of progression or intolerance), and had adequate haematological and biochemical parameters. Patients were randomly assigned (1:1) to receive intravenous ramucirumab (8 mg/kg) or placebo every 2 weeks, plus best supportive care, until disease progression, unacceptable toxicity, or death. Randomisation was stratified by geographic region and cause of liver disease with a stratified permuted block method. Patients, medical staff, investigators, and the funder were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01140347. FINDINGS: Between Nov 4, 2010, and April 18, 2013, 565 patients were enrolled, of whom 283 were assigned to ramucirumab and 282 were assigned to placebo. Median overall survival for the ramucirumab group was 9·2 months (95% CI 8·0-10·6) versus 7·6 months (6·0-9·3) for the placebo group (HR 0·87 [95% CI 0·72-1·05]; p=0·14). Grade 3 or greater adverse events occurring in 5% or more of patients in either treatment group were ascites (13 [5%] of 277 patients treated with ramucirumab vs 11 [4%] of 276 patients treated with placebo), hypertension (34 [12%] vs ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm progression (18 [6%] vs 11 [4%]), increased aspartate aminotransferase concentration (15 [5%] vs 23 [8%]), thrombocytopenia (13 [5%] vs one [<1%]), hyperbilirubinaemia (three [1%] vs 13 [5%]), and increased blood bilirubin (five [2%] vs 14 [5%]). The most frequently reported (≥1%) treatment-emergent serious adverse event of any grade or grade 3 or more was malignant neoplasm progression. INTERPRETATION: Second-line treatment with ramucirumab did not significantly improve survival over placebo in patients with advanced hepatocellular carcinoma. No new safety signals were noted in eligible patients and the safety profile is manageable. FUNDING: Eli Lilly and Co.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031316
003      
CZ-PrNML
005      
20151014130052.0
007      
ta
008      
151005s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(15)00050-9 $2 doi
035    __
$a (PubMed)26095784
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Zhu, Andrew X $u Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: azhu@partners.org.
245    10
$a Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial / $c AX. Zhu, JO. Park, BY. Ryoo, CJ. Yen, R. Poon, D. Pastorelli, JF. Blanc, HC. Chung, AD. Baron, TE. Pfiffer, T. Okusaka, K. Kubackova, J. Trojan, J. Sastre, I. Chau, SC. Chang, PB. Abada, L. Yang, JD. Schwartz, M. Kudo, . ,
520    9_
$a BACKGROUND: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. METHODS: In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy, had Child-Pugh A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, had previously received sorafenib (stopped because of progression or intolerance), and had adequate haematological and biochemical parameters. Patients were randomly assigned (1:1) to receive intravenous ramucirumab (8 mg/kg) or placebo every 2 weeks, plus best supportive care, until disease progression, unacceptable toxicity, or death. Randomisation was stratified by geographic region and cause of liver disease with a stratified permuted block method. Patients, medical staff, investigators, and the funder were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01140347. FINDINGS: Between Nov 4, 2010, and April 18, 2013, 565 patients were enrolled, of whom 283 were assigned to ramucirumab and 282 were assigned to placebo. Median overall survival for the ramucirumab group was 9·2 months (95% CI 8·0-10·6) versus 7·6 months (6·0-9·3) for the placebo group (HR 0·87 [95% CI 0·72-1·05]; p=0·14). Grade 3 or greater adverse events occurring in 5% or more of patients in either treatment group were ascites (13 [5%] of 277 patients treated with ramucirumab vs 11 [4%] of 276 patients treated with placebo), hypertension (34 [12%] vs ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm progression (18 [6%] vs 11 [4%]), increased aspartate aminotransferase concentration (15 [5%] vs 23 [8%]), thrombocytopenia (13 [5%] vs one [<1%]), hyperbilirubinaemia (three [1%] vs 13 [5%]), and increased blood bilirubin (five [2%] vs 14 [5%]). The most frequently reported (≥1%) treatment-emergent serious adverse event of any grade or grade 3 or more was malignant neoplasm progression. INTERPRETATION: Second-line treatment with ramucirumab did not significantly improve survival over placebo in patients with advanced hepatocellular carcinoma. No new safety signals were noted in eligible patients and the safety profile is manageable. FUNDING: Eli Lilly and Co.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a hepatocelulární karcinom $x farmakoterapie $x mortalita $x patologie $7 D006528
650    _2
$a interval spolehlivosti $7 D016001
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a nádory jater $x farmakoterapie $x mortalita $x patologie $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a niacinamid $x analogy a deriváty $x terapeutické užití $7 D009536
650    _2
$a výběr pacientů $7 D018579
650    _2
$a fenylmočovinové sloučeniny $x terapeutické užití $7 D010671
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a indukce remise $7 D012074
650    _2
$a analýza přežití $7 D016019
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Park, Joon Oh $u Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
700    1_
$a Ryoo, Baek-Yeol $u Asan Medical Center, University of Ulsan School of Medicine, Seoul, South Korea.
700    1_
$a Yen, Chia-Jui $u National Cheng Kung University Hospital, Tainan City, Taiwan.
700    1_
$a Poon, Ronnie $u The University of Hong Kong, Hong Kong.
700    1_
$a Pastorelli, Davide $u Istituto Oncologico Veneto IRCCS, Padova, Italy.
700    1_
$a Blanc, Jean-Frederic $u Hopital Saint-Andre, Bordeaux, France.
700    1_
$a Chung, Hyun Cheol $u Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.
700    1_
$a Baron, Ari D $u California Pacific Medical Center, San Francisco, CA, USA.
700    1_
$a Pfiffer, Tulio Eduardo Flesch $u Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil.
700    1_
$a Okusaka, Takuji $u National Cancer Center Hospital, Tokyo, Japan.
700    1_
$a Kubackova, Katerina $u University Hospital in Motol, Prague, Czech Republic.
700    1_
$a Trojan, Jorg $u University Hospital Cancer Center, Frankfurt, Germany.
700    1_
$a Sastre, Javier $u Hospital Clínico San Carlos, Madrid, Spain.
700    1_
$a Chau, Ian $u Royal Marsden Hospital, Surrey, UK.
700    1_
$a Chang, Shao-Chun $u Eli Lilly and Company, Indianapolis, IN, USA.
700    1_
$a Abada, Paolo B $u Eli Lilly and Company, Indianapolis, IN, USA. $7 gn_A_00000137
700    1_
$a Yang, Ling $u Eli Lilly and Company, Bridgewater, NJ, USA.
700    1_
$a Schwartz, Jonathan D $u Stemline Therapeutics Inc, New York, NY, USA.
700    1_
$a Kudo, Masatoshi $u Kinki University School of Medicine, Osaka-Sayama City, Osaka, Japan.
700    1_
$a ,
773    0_
$w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 16, č. 7 (2015), s. 859-70
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26095784 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20151014130242 $b ABA008
999    __
$a ok $b bmc $g 1092192 $s 914442
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 16 $c 7 $d 859-70 $e 20150618 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20151005

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace